Avenue Capital Surpluse vs Total Current Assets Analysis

ATXI Stock

USD 2.06 0.02 0.98%

Avenue Therapeutics financial indicator trend analysis is way more than just evaluating Avenue Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avenue Therapeutics is a good investment. Please check the relationship between Avenue Therapeutics Capital Surpluse and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.

Capital Surpluse vs Total Current Assets

Capital Surpluse vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avenue Therapeutics Capital Surpluse account and Total Current Assets. At this time, the significance of the direction appears to have weak relationship.

The correlation between Avenue Therapeutics' Capital Surpluse and Total Current Assets is 0.35. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Avenue Therapeutics, assuming nothing else is changed. The correlation between historical values of Avenue Therapeutics' Capital Surpluse and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Avenue Therapeutics are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Capital Surpluse i.e., Avenue Therapeutics' Capital Surpluse and Total Current Assets go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Capital Surpluse

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most indicators from Avenue Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avenue Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.The Avenue Therapeutics' current Issuance Of Capital Stock is estimated to increase to about 7.9 M, while Selling General Administrative is projected to decrease to under 3.3 M.

Avenue Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Assets	Retained Earnings Total Equity	Other Current Assets
Total Assets		0.48	0.21	0.0	0.94	0.92	0.51	-0.87	-0.2	0.53	0.95	1.0	0.13	0.18	-0.46	-0.52	0.35	0.38	-0.34	0.09	1.0	0.52	0.1	0.0	-0.14	-0.11
Short Long Term Debt Total	0.48		0.49	0.05	0.59	0.62	0.99	-0.69	-0.78	0.23	0.58	0.46	0.7	0.23	-0.97	-0.72	0.8	0.84	-0.51	-0.3	0.48	0.99	0.67	-0.07	-0.71	-0.77
Other Current Liab	0.21	0.49		0.21	0.27	0.26	0.5	-0.51	-0.61	0.03	0.43	0.19	0.52	0.7	-0.51	-0.39	0.58	0.61	-0.22	-0.14	0.21	0.5	0.61	0.01	-0.63	-0.6
Total Current Liabilities	0.0	0.05	0.21		-0.26	-0.28	0.09	0.21	0.37	0.42	-0.07	-0.03	-0.51	0.03	-0.06	0.42	-0.38	-0.39	0.77	0.18	0.0	0.09	-0.37	0.57	0.4	0.32
Total Stockholder Equity	0.94	0.59	0.27	-0.26		1.0	0.6	-0.95	-0.49	0.4	0.93	0.94	0.39	0.17	-0.6	-0.73	0.62	0.62	-0.64	-0.16	0.94	0.6	0.33	-0.17	-0.42	-0.38
Net Tangible Assets	0.92	0.62	0.26	-0.28	1.0		0.62	-0.94	-0.51	0.39	0.92	0.92	0.42	0.13	-0.62	-0.75	0.64	0.65	-0.66	-0.19	0.92	0.62	0.38	-0.18	-0.43	-0.4
Current Deferred Revenue	0.51	0.99	0.5	0.09	0.6	0.62		-0.71	-0.75	0.25	0.62	0.49	0.68	0.3	-0.96	-0.7	0.77	0.82	-0.48	-0.22	0.51	1.0	0.63	-0.04	-0.69	-0.74
Net Debt	-0.87	-0.69	-0.51	0.21	-0.95	-0.94	-0.71		0.63	-0.36	-0.95	-0.86	-0.54	-0.38	0.69	0.74	-0.73	-0.76	0.66	0.11	-0.87	-0.71	-0.47	0.11	0.59	0.55
Retained Earnings	-0.2	-0.78	-0.61	0.37	-0.49	-0.51	-0.75	0.63		0.11	-0.41	-0.2	-0.9	-0.33	0.82	0.8	-0.99	-0.97	0.82	0.55	-0.2	-0.74	-0.86	0.33	0.98	0.97
Accounts Payable	0.53	0.23	0.03	0.42	0.4	0.39	0.25	-0.36	0.11		0.35	0.47	-0.38	-0.23	-0.23	0.21	-0.01	-0.03	0.1	0.04	0.53	0.25	-0.34	0.8	0.21	0.02
Cash	0.95	0.58	0.43	-0.07	0.93	0.92	0.62	-0.95	-0.41	0.35		0.95	0.37	0.39	-0.56	-0.65	0.53	0.58	-0.46	0.07	0.95	0.62	0.3	-0.12	-0.38	-0.31
Cash And Short Term Investments	1.0	0.46	0.19	-0.03	0.94	0.92	0.49	-0.86	-0.2	0.47	0.95		0.15	0.18	-0.44	-0.55	0.34	0.38	-0.35	0.08	1.0	0.5	0.11	-0.07	-0.14	-0.09
Common Stock Total Equity	0.13	0.7	0.52	-0.51	0.39	0.42	0.68	-0.54	-0.9	-0.38	0.37	0.15		0.43	-0.67	-0.79	0.87	0.92	-0.78	-0.3	0.13	0.67	0.93	-0.52	-0.92	-0.87
Common Stock Shares Outstanding	0.18	0.23	0.7	0.03	0.17	0.13	0.3	-0.38	-0.33	-0.23	0.39	0.18	0.43		-0.18	-0.28	0.29	0.41	-0.13	0.43	0.18	0.31	0.39	-0.19	-0.46	-0.33
Long Term Debt Total	-0.46	-0.97	-0.51	-0.06	-0.6	-0.62	-0.96	0.69	0.82	-0.23	-0.56	-0.44	-0.67	-0.18		0.75	-0.85	-0.84	0.55	0.46	-0.46	-0.96	-0.64	0.1	0.75	0.79
Non Current Liabilities Total	-0.52	-0.72	-0.39	0.42	-0.73	-0.75	-0.7	0.74	0.8	0.21	-0.65	-0.55	-0.79	-0.28	0.75		-0.85	-0.84	0.79	0.45	-0.52	-0.69	-0.74	0.66	0.76	0.65
Capital Surpluse	0.35	0.8	0.58	-0.38	0.62	0.64	0.77	-0.73	-0.99	-0.01	0.53	0.34	0.87	0.29	-0.85	-0.85		0.97	-0.86	-0.55	0.35	0.77	0.81	-0.31	-0.95	-0.94
Other Stockholder Equity	0.38	0.84	0.61	-0.39	0.62	0.65	0.82	-0.76	-0.97	-0.03	0.58	0.38	0.92	0.41	-0.84	-0.84	0.97		-0.83	-0.38	0.38	0.82	0.87	-0.31	-0.94	-0.93
Total Liab	-0.34	-0.51	-0.22	0.77	-0.64	-0.66	-0.48	0.66	0.82	0.1	-0.46	-0.35	-0.78	-0.13	0.55	0.79	-0.86	-0.83		0.46	-0.34	-0.48	-0.65	0.44	0.8	0.76
Short Long Term Debt	0.09	-0.3	-0.14	0.18	-0.16	-0.19	-0.22	0.11	0.55	0.04	0.07	0.08	-0.3	0.43	0.46	0.45	-0.55	-0.38	0.46		0.09	-0.2	-0.4	0.25	0.43	0.46
Total Current Assets	1.0	0.48	0.21	0.0	0.94	0.92	0.51	-0.87	-0.2	0.53	0.95	1.0	0.13	0.18	-0.46	-0.52	0.35	0.38	-0.34	0.09		0.52	0.1	0.0	-0.14	-0.11
Short Term Debt	0.52	0.99	0.5	0.09	0.6	0.62	1.0	-0.71	-0.74	0.25	0.62	0.5	0.67	0.31	-0.96	-0.69	0.77	0.82	-0.48	-0.2	0.52		0.63	-0.04	-0.69	-0.74
Common Stock	0.1	0.67	0.61	-0.37	0.33	0.38	0.63	-0.47	-0.86	-0.34	0.3	0.11	0.93	0.39	-0.64	-0.74	0.81	0.87	-0.65	-0.4	0.1	0.63		-0.49	-0.83	-0.81
Other Assets	0.0	-0.07	0.01	0.57	-0.17	-0.18	-0.04	0.11	0.33	0.8	-0.12	-0.07	-0.52	-0.19	0.1	0.66	-0.31	-0.31	0.44	0.25	0.0	-0.04	-0.49		0.36	0.13
Retained Earnings Total Equity	-0.14	-0.71	-0.63	0.4	-0.42	-0.43	-0.69	0.59	0.98	0.21	-0.38	-0.14	-0.92	-0.46	0.75	0.76	-0.95	-0.94	0.8	0.43	-0.14	-0.69	-0.83	0.36		0.96
Other Current Assets	-0.11	-0.77	-0.6	0.32	-0.38	-0.4	-0.74	0.55	0.97	0.02	-0.31	-0.09	-0.87	-0.33	0.79	0.65	-0.94	-0.93	0.76	0.46	-0.11	-0.74	-0.81	0.13	0.96

Click cells to compare fundamentals

Avenue Therapeutics Account Relationship Matchups

Avenue Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.9M	3.2M	4.0M	6.8M	1.9M	1.8M
Other Current Liab	1.7M	714K	147K	3.4M	795K	1.1M
Total Current Liabilities	2.1M	886K	509K	3.6M	1.2M	2.2M
Total Stockholder Equity	6.8M	2.4M	3.5M	3.9M	1.6M	2.9M
Net Tangible Assets	(631K)	6.8M	2.4M	3.5M	4.0M	2.8M
Net Debt	(8.7M)	(3.1M)	(3.8M)	(6.7M)	(1.8M)	(1.9M)
Retained Earnings	(68.1M)	(73.3M)	(77.0M)	(80.6M)	(90.9M)	(86.4M)
Accounts Payable	368K	172K	362K	150K	401K	778.9K
Cash	8.7M	3.1M	3.8M	6.7M	1.8M	1.7M
Cash And Short Term Investments	8.7M	3.1M	3.8M	6.7M	1.8M	1.7M
Common Stock Shares Outstanding	1.0M	1.1M	1.1M	2.2M	141.2K	134.2K
Liabilities And Stockholders Equity	8.9M	3.2M	4.0M	6.8M	1.9M	1.8M
Non Current Liabilities Total	0.0	3.6M	368K	172K	362K	949.0
Capital Surpluse	38.9M	41.6M	74.9M	75.6M	87.0M	91.3M
Other Stockholder Equity	74.9M	75.6M	80.4M	84.5M	92.5M	59.9M
Total Liab	2.1M	886K	509K	3.6M	1.2M	1.1M
Total Current Assets	8.9M	3.2M	4.0M	6.8M	1.9M	1.8M
Other Assets	1.9M	170K	113K	137.0	67K	63.7K
Other Current Assets	170K	113K	107K	137K	67K	129.6K
Net Invested Capital	6.8M	2.4M	3.5M	3.9M	1.6M	1.5M
Net Working Capital	6.8M	2.4M	3.5M	3.3M	654K	621.3K

Currently Active Assets on Macroaxis

ESRT	Empire State Realty
C	Citigroup
C	Citigroup
GOOG	Alphabet Inc Class C
DD	Dupont De Nemours

When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:

How To Invest In Avenue

Details

Is Avenue Stock a good investment?

Details

What is Avenue Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.76)

Earnings Share

24.78

Return On Assets

(2.01)

Return On Equity

(5.35)

The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Avenue Capital Surpluse vs Total Current Assets Analysis

Capital Surpluse vs Total Current Assets

Capital Surpluse vs Total Current Assets Correlation Analysis

Correlation Coefficient

Capital Surpluse

Total Current Assets

Avenue Therapeutics fundamental ratios Correlations

Avenue Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Avenue Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Short Term Debt	+ 1.0	Current Deferred Revenue
Total Current Assets	+ 1.0	Cash And Short Term Investments
Current Deferred Revenue	+ 0.99	Short Long Term Debt Total

Capital Surpluse	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Long Term Debt Total	- 0.97	Short Long Term Debt Total
Short Term Debt	- 0.96	Long Term Debt Total
Long Term Debt Total	- 0.96	Current Deferred Revenue
Retained Earnings Total Equity	- 0.95	Capital Surpluse